Trial record 1 of 1 for:    NCT00569842
Previous Study | Return to List | Next Study

Investigation of the Cylex® ImmuKnow® Assay

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Indiana University ( Indiana University School of Medicine )
ClinicalTrials.gov Identifier:
NCT00569842
First received: December 5, 2007
Last updated: September 10, 2014
Last verified: September 2014
  Purpose

Currently, there is no accurate way of predicting the occurrence of Graft vs Host Disease (GvHD) or infection. The purpose of this study is to analyze blood with the ImmuKnow® Assay to see if doctors can detect which patients are at risk for GvHD and for getting an infection before they occur.


Condition
Leukemia
Non-Hodgkin's Lymphoma
Chronic Lymphocytic Leukemia
Hodgkin's Disease
Multiple Myeloma
Myelodysplastic Syndromes
Myeloproliferative Disorders
Aplastic Anemia
Chronic Myelogenous Leukemia

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Investigation of the Cylex® ImmuKnow® Assay

Resource links provided by NLM:


Further study details as provided by Indiana University:

Biospecimen Retention:   None Retained

None to be retained.


Enrollment: 45
Study Start Date: November 2007
Study Completion Date: December 2012
Primary Completion Date: February 2010 (Final data collection date for primary outcome measure)
Groups/Cohorts
observational

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients who are undergoing allogeneic HSCT using a myeloablative preparative regimen for any of the following disorders are eligible:

  1. Acute leukemia
  2. Non-Hodgkin's Lymphoma
  3. Chronic lymphocytic leukemia
  4. Hodgkin's disease
  5. Multiple myeloma
  6. Myelodysplastic Syndromes
  7. Myeloproliferative Disorders
  8. Aplastic Anemia
  9. Chronic myelogenous leukemia
Criteria

Inclusion Criteria:

Patients who are undergoing allogeneic HSCT using a myeloablative preparative regimen for any of the following disorders are eligible:

  1. Acute leukemia
  2. Non-Hodgkin's Lymphoma
  3. Chronic lymphocytic leukemia
  4. Hodgkin's disease
  5. Multiple myeloma
  6. Myelodysplastic Syndromes
  7. Myeloproliferative Disorders
  8. Aplastic Anemia
  9. Chronic myelogenous leukemia
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00569842

Locations
United States, Indiana
Indiana Universtiy Simon Cancer Center
Indianapolis, Indiana, United States, 46202
Sponsors and Collaborators
Indiana University School of Medicine
Investigators
Principal Investigator: Sherif Farag, MD, PhD Indiana University Simon Cancer Center
  More Information

Additional Information:
No publications provided

Responsible Party: Indiana University ( Indiana University School of Medicine )
ClinicalTrials.gov Identifier: NCT00569842     History of Changes
Other Study ID Numbers: 0710-11/ IUCRO-0207
Study First Received: December 5, 2007
Last Updated: September 10, 2014
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Anemia, Aplastic
Hodgkin Disease
Leukemia
Leukemia, Lymphocytic, Chronic, B-Cell
Leukemia, Lymphoid
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Leukemia, Myeloid
Lymphoma, Non-Hodgkin
Multiple Myeloma
Myelodysplastic Syndromes
Myeloproliferative Disorders
Neoplasms, Plasma Cell
Preleukemia
Anemia
Blood Protein Disorders
Bone Marrow Diseases
Cardiovascular Diseases
Hematologic Diseases
Hemorrhagic Disorders
Hemostatic Disorders
Immune System Diseases
Immunoproliferative Disorders
Leukemia, B-Cell
Lymphatic Diseases
Lymphoma
Lymphoproliferative Disorders
Neoplasms
Neoplasms by Histologic Type
Paraproteinemias
Precancerous Conditions

ClinicalTrials.gov processed this record on October 30, 2014